intellectual property11 Mar 2015 19:28
Underpinning the development and commercialisation strategy is Tissue Regenix's intellectual property portfolio. The core decellularisation process, which encompasses all of the Company's products, is covered by a process patent. The Company also files, where possible, individual product patents. In addition, significant know-how is retained within the Company.